Perioperative Outcomes After Uni- Versus Bilateral Total Knee Arthroplasty
Shane C. Reid, BA
Admitting Service and Morbidity and Mortality in Elderly Patients after Hip Fractures
James Mok, MD
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Versus Enoxaparin for Thromboprophylaxis After Total Knee Replacement
Alexander GG Turpie, MD
The Effect of Obesity on the Revision Rate of Minimally Invasive Unicompartmental Arthroplasty
William Hamilton, MD
AAOS Clinical Guidelines: Prevention of Symptomatic Pulmonary Embolism in Patients undergoing THA and TKA
Paul F. Lachiewicz, MD
Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients after Total Knee Arthroplasty
Fuji T, Fujita S, Tachibana S, Kawai Y
Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors
Lu G, DeGuzman FR, Lakhotia S, Hollenbach SJ, Phillips DR, Sinha U
A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma. A California Consortium Study
Kirschbaum M, Popplewell L, Nademanee AP, et. al.
Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years
Dahl OE, Kurth AA, Rosencher N, et. al.
Final Results From A Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-risk Myelodysplastic Syndromes
Sekeres MA, List AF, Cuthbertson D, Paquette R, et al.
Safe Treatment of Pulmonary Embolism on An Outpatient Basis
Kovacs MJ, Hawel JDE, Rekman JF, Lazo-Langner A
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding
Turpie AGG, Bauer KA, Davidson BA, Gent M, et al.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4
Turpie AGG, Bauer KA, Davidson BA, Gent M, et al.
Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study
Turpie AGG, Hull RD, Schellong SM, Tapson VF, et al.
Are Hospitals Following Guidelines for VTE Prevention? The Venous Thromboembolism Study to Assess the Rate of Thromboprophylaxis
Amin A, Spyropoulos A, Dobesh P, Shorr A, et al.
Systemic Therapy Utilization Patterns among US Dermatologists and Oncologists Treating Cutaneous T-Cell Lymphoma
Pinter-Brown L, Wisniewski T, Katic B, et al.
Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK
Coffey G, Luan P, Delaney S, Pandey A, et al.
Specific Pharmacological Targeting of Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy
Delaney S, Sim D, Abe K, Nanda N, Siu G, et al.
Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study
Ashrani AA, Heit JA, Crusan DJ, Petterson TM, et al.
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
Silverman LR, Verma A, Odchimar-Reissig R, et al.
Slide Decks from 2007 ISTH Annual Meeting
July 6-12, 2007 - Geneva, Switzerland
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee Replacement: The BISTRO II Randomized Trial
Eriksson BI, Dahl OE, Buller HR, et al.
The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism Following Major Orthopedic Surgery
Caprini JA, Hwang E, Hantel S, Schnee J, Eriksson B
Dabigatran Etexilate Versus Enoxaparin in Preventing Venous Thromboembolism Following Total Knee Arthroplasty
Friedman RJ, Caprini JA, Comp PC, et al.
Late Breaking Clinical Trial - A Dose Finding Study Of The Oral Direct Factor Xa Inhibitor Apixaban in the Treatment of Patients with Acute Symptomatic Deep Vein Thrombosis: The Botticelli Investigators
Buller HR
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Patients After Total Knee Replacement: A Phase II Dose-Ranging Study
Turpie AG, Fisher WD, Bauer KA, et al.
Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement
Eriksson BI, Borris L, Dahl OE, et al.
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery – Results of the RECORD 3 Study
Lassen MR,Turpie AG,Rosencher N, et al.
Treatment of Proximal Deep Vein Thrombosis (DVT): Rivaroxaban Once or Twice Daily Had Similar Efficacy and Safety to Standard Therapy in Phase II Studies
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement (THR)
Eriksson BI,Misselwitz F,Mueck F, et al.
Dabigatran Etexilate Is Effective And Safe For The Extended Prevention Of Venous Thromboembolism Following Total Hip Replacement
BI Eriksson, OE Dahl, N Rosencher, et al.
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia
J. M. Walenga, W. P. Jeske, M. Prechel, et al.